CStone announces major clinical validation milestone for CS2009 at ESMO 2026: Data from more than 300 patients Support Mechanism, Safety and Broad Antitumor Activity

Summary

CS2009, an innovative PD-1/VEGF/CTLA-4 tri-specific antibody, demonstrates a differentiated profile through synergistic triple pathway targeting, favorable tolerability and encouraging efficacy across multiple solid tu...